Interleukin-12: Biological properties and clinical application

被引:455
作者
Del Vecchio, Michele
Bajetta, Emilio
Canova, Stefania
Lotze, Michael T.
Wesa, Amy
Parmiani, Giorgio
Anichini, Andrea
机构
[1] Ist Nazl Studio & Cura Tumori, Fdn IRCCS, Med Oncol Unit 2, Dept Expt Oncol, I-20133 Milan, Italy
[2] Ist Nazl Studio & Cura Tumori, Fdn IRCCS, Human Tumor Immunobiol Unit, Dept Expt Oncol, I-20133 Milan, Italy
[3] Ist Sci San Raffaele, Unit Immuno Biotherapy Solid Tumors, Milan, Italy
[4] Univ Pittsburgh, Pittsburgh Canc Inst, Translat Res Mol Med Inst, Pittsburgh, PA USA
[5] Univ Pittsburgh, Sch Med, Dept Dermatol, Pittsburgh, PA USA
关键词
D O I
10.1158/1078-0432.CCR-07-0776
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interleukin-12 (IL-12) is a heterodimeric protein, first recovered from EBV-transformed B cell lines. It is a multifunctional cytokine, the properties of which bridge innate and adaptive immunity, acting as a key regulator of cell-mediated immune responses through the induction of T helper 1 differentiation. By promoting IFN-gamma production, proliferation, and cytolytic activity of natural killer and Tcells, IL-12 induces cellular immunity. In addition, IL-12 induces an antiangiogenic program mediated by IFN-gamma- inducible genes and by lymphocyte-endothelial cell cross-talk. The immunomodulating and antiangiogenic functions of IL-12 have provided the rationale for exploiting this cytokine as an anticancer agent, In contrast with the significant antitumor and antimetastatic activity of IL-12, documented in several preclinical studies, clinical trials with IL-12, used as a single agent, or as a vaccine adjuvant, have shown limited efficacy in most instances. More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and should be evaluated as therapeutic agents with considerable potential in cancer patients.
引用
收藏
页码:4677 / 4685
页数:9
相关论文
共 96 条
  • [1] Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: Phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma
    Alatrash, G
    Hutson, TE
    Molto, L
    Richmond, A
    Nemec, C
    Mekhail, T
    Elson, P
    Tannenbaum, C
    Olencki, T
    Finke, J
    Bukowski, RM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 2891 - 2900
  • [2] Atkins MB, 1997, CLIN CANCER RES, V3, P409
  • [3] Bajetta E, 1998, CLIN CANCER RES, V4, P75
  • [4] Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells
    Batten, Marcel
    Li, Ji
    Yi, Sothy
    Kljavin, Noelyn M.
    Danilenko, Dimitry M.
    Lucas, Sophie
    Lee, James
    de Sauvage, Frederic J.
    Ghilardi, Nico
    [J]. NATURE IMMUNOLOGY, 2006, 7 (09) : 929 - 936
  • [5] T cell-independent, TLR-induced IL-12p70 production in primary human monocytes
    Bekeredjian-Ding, Isabelle
    Roth, Susanne Ilona
    Gilles, Stefanie
    Giese, Thomas
    Ablasser, Andrea
    Hornung, Veit
    Endres, Stefan
    Hartmann, Gunther
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 176 (12) : 7438 - 7446
  • [6] Regulatory T cells in cancer
    Beyer, Marc
    Schultze, Joachim L.
    [J]. BLOOD, 2006, 108 (03) : 804 - 811
  • [7] ANTITUMOR AND ANTIMETASTATIC ACTIVITY OF INTERLEUKIN-12 AGAINST MURINE TUMORS
    BRUNDA, MJ
    LUISTRO, L
    WARRIER, RR
    WRIGHT, RB
    HUBBARD, BR
    MURPHY, M
    WOLF, SF
    GATELY, MK
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (04) : 1223 - 1230
  • [8] Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12
    Cavallo, F
    Signorelli, P
    Giovarelli, M
    Musiani, P
    Modesti, A
    Brunda, MJ
    Colombo, MP
    Forni, G
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (14) : 1049 - 1058
  • [9] Cavallo F, 2001, CANCER RES, V61, P3518
  • [10] Cebon Jonathan, 2003, Cancer Immun, V3, P7